Related drugs

Showing the single result

  • Breast cancer , Late childhood neuroblastoma


    【Product name】Alkeran

    [English common name]Melphalan

    [Chinese common name]Melphalan

    [English name]Melphalan HCl, Melphalan 2HCl, l-phenylalanine mustard

    [Chinese other name]Melfal, Melphalan, cancer Kyan, Milfair

    [Indications] This product can be used with a variety of tumors, in single chemotherapy and combination chemotherapy,Multiple myelomaThe drug of choice. CorrectSpermato cell tumor,Breast cancer,Ovarian cancer,Chronic leukemia,Polycythemia vera,Malignant lymphoma,Late childhood neuroblastoma,Thyroid cancereffective. Arterial infusion for the treatment of limb malignancies such as malignant melanoma, soft tissue sarcoma and osteosarcoma has a good effect, even for the treatment of certain autoimmune diseases and to prevent rejection during organ transplantation.

    Multiple myeloma:
    A typical dose is 0.15 mg per kilogram of body weight per day, taken in four divided doses, and repeated for six weeks. Prolonged treatment for those who respond to treatment will not change the effect. The combination of melphalan and prednisone may be more effective than single use.
    Ovarian adenocarcinoma:
    A typical treatment regimen is 0.2 mg per kilogram of body weight per day for five days, repeated every 4 to 8 weeks or when the peripheral blood is restored; the dose should be reduced when bone marrow toxicity occurs.
    Advanced breast cancer:
    Oral melphalan daily 0.15 mg per kilogram of body weight or 6 mg per square meter of body surface area for a total of 5 days, repeated treatments every six weeks, can also be treated with intravenous melphalan.
    True erythrocytosis:
    Induction of remission, use 6 to 10 mg daily for 5 to 7 days, then 2 to 4 mg per day until the symptoms can be satisfactorily controlled. The maintenance dose can be 2 to 6 mg per week. Care must be taken during the patient. The hematology control is performed on the ground, and the dose is appropriately adjusted based on the blood cell count result.
    Patients with renal insufficiency:
    Based on current pharmacokinetic data, oral melphalan is not recommended for patients with moderate to severe renal insufficiency, but the initial dose should be carefully reduced.

    [Storage]Store in a dark, cool, dry place.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

zh_CN简体中文 en_USEnglish